← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
IM19 CAR-T (IM19 CAR-T)
Beijing Immunochina Medical Scienc…·Leukemia
11 trials
Overview
Program
IM19 CAR-T
Overview
Company
Beijing Immunochina Medical Science & Technology Co., Ltd.
Overview
Modality
CGT
Overview
Target
Leukemia
Overview
Indication
Leukemia
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review.. This study aims to evaluate the efficacy and safety of IM19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell, in patients with refractory systemic lupus erythematosus (SLE), with a particular focus on lupus nephritis (LN). This is an …
Toxicology
CRS
Reported
Clinical
Safety signal
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review.. This study aims to evaluate the efficacy and safety of IM19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell, in patients with refractory systemic lupus erythematosus (SLE), with a particular focus on lupus nephritis (LN). This is an …
Clinical
Program phase
PHASE_2